Atriance Европейски съюз - български - EMA (European Medicines Agency)

atriance

sandoz pharmaceuticals d.d. - неларабин - Прекурсорна Т-клетъчна лимфобластна левкемия-лимфом - Антинеопластични средства - nelarabine е показан за лечение на пациентите с т-клетъчен остър лимфобластным левкемия (Т-ол) и т-клетъчна лимфоцитна лимфом (Т-ЛБЛ), чието заболяване не се отговаря, или се е появил рецидив след лечение с най-малко два режима на химиотерапия. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.

Alunbrig Европейски съюз - български - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - Карцином, недребноклетъчен белодроб - Антинеопластични средства - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Alzancer 10 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

alzancer 10 mg film - coated tablets

10 mg film - coated tablets

Alzancer 5 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

alzancer 5 mg film - coated tablets

5 mg film - coated tablets

Alzancer Odt 5 mg orodispersible tablets България - български - Изпълнителна агенция по лекарствата

alzancer odt 5 mg orodispersible tablets

5 mg orodispersible tablets

Alzancer Odt 10 mg orodispersible tablets България - български - Изпълнителна агенция по лекарствата

alzancer odt 10 mg orodispersible tablets

10 mg orodispersible tablets

Lithibalance 500 mg tablets България - български - Изпълнителна агенция по лекарствата

lithibalance 500 mg tablets

500 mg tablets

Opdualag Европейски съюз - български - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - Меланомът - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Cabometyx Европейски съюз - български - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Антинеопластични средства - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Teysuno Европейски съюз - български - EMA (European Medicines Agency)

teysuno

nordic group b.v. - тегафур, gimeracil, oteracil - Стомашни неоплазми - Антинеопластични средства - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.